Citadel Advisors
TSHA icon

Citadel Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Citadel Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$217K Sell
48,500
-33,500
-41% -$156K ﹤0.01% 11252
2025
Q4 		$451K Buy
82,000
+56,300
+219% +$273K ﹤0.01% 9281
2025
Q3 		$84K Buy
25,700
+8,700
+51% +$24.6K ﹤0.01% 11946
2025
Q2 		$39.3K Buy
17,000
+12,300
+262% +$26.7K ﹤0.01% 11886
2025
Q1 		$6.53K Sell
4,700
-3,100
-40% -$5.18K ﹤0.01% 13747
2024
Q4 		$13.5K Sell
7,800
-5,500
-41% -$11.4K ﹤0.01% 13442
2024
Q3 		$26.7K Sell
13,300
-6,000
-31% -$13.2K ﹤0.01% 12539
2024
Q2 		$43.2K Buy
19,300
+11,100
+135% +$32.3K ﹤0.01% 11926
2024
Q1 		$23.5K Buy
8,200
+6,800
+486% +$14.2K ﹤0.01% 12894
2023
Q4 		$2.48K Sell
1,400
-31,300
-96% -$62.4K ﹤0.01% 13691
2023
Q3 		$103K Buy
32,700
+31,600
+2,873% +$59K ﹤0.01% 10855
2023
Q2 		$727 Sell
1,100
-100
-8% -$72 ﹤0.01% 14058
2023
Q1 		$957 Sell
1,200
-19,500
-94% -$25.2K ﹤0.01% 14390
2022
Q4 		$46.8K Buy
+20,700
New +$41.9K ﹤0.01% 12216

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's TSHA Position: Q1 2026 in Review

Citadel Advisors reduced its Taysha Gene Therapies (TSHA) stake by 78% in Q1 2026, selling an estimated $6.71M and leaving 411,135 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #6255.

Citadel Advisors first reported a position in TSHA in Q3 2020 and has held it in 19 quarters since. The position peaked at $10.2M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Citadel Advisors held 411,135 shares of Taysha Gene Therapies worth $1.84M as of Q1 2026.
  • Citadel Advisors sold 1,443,720 Taysha Gene Therapies shares in Q1 2026, an estimated $6.71M.
  • Taysha Gene Therapies made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6255 holding.
  • Citadel Advisors first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Taysha Gene Therapies position peaked at $10.2M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.